Clinical Trials Logo

Autistic Disorder clinical trials

View clinical trials related to Autistic Disorder.

Filter by:

NCT ID: NCT00298246 Completed - Seizures Clinical Trials

Clinical and Immunological Investigations of Subtypes of Autism

Start date: February 22, 2006
Phase: N/A
Study type: Observational

The purpose of this study is to learn more about autism and its subtypes. Autism is a developmental disorder in which children have problems with communication and social skills and display restricted interests and repetitive behaviors. This study has several goals. One aim is to look at types of autism that are known, such as the regressive subtype, (where skills are lost). We will explore whether there is a unique change in immune functioning related to this subtype. Another aim is to serve as one of the sites that will pilot a larger natural history study, entitled Autism Phenome Project. The goal is to further understand autism by identifying other subtypes. We will look at several types of medical issues that may be related to autism, including immunologic problems. Children will be followed over the course of several years. We aim to capture medical problems that may be related to autism as they develop, and study outcomes in areas such as behavior and language, in order to explore known and new subtypes of autism. Normally developing children (aged 1) with autism (age 1, and developmental delays other than autism (age 1), may be eligible for this study. Depending on each child's study group and age, participants may undergo the following tests and procedures: Baseline Visit - Medical and developmental history, physical examination, psychological, cognitive and medical tests to assess symptoms of autism or other developmental disorders, photographs of the child's face, collection of hair, urine and baby teeth samples. If available, hair samples from the baby's first haircut and from the biological mother's hair are also collected. - Overnight electroencephalogram (EEG): A special cap with electrodes is placed on the child's head to measure brain waves (brain electrical activity) while the child sleeps in the hospital overnight. Healthy volunteers do not undergo this procedure. - Magnetic resonance imaging (MRI) scan: The child stays in the scanner, lying still for 10 to 15 minutes at a time. Since it may be difficult for the child to lie still, the test may be scheduled for a time when the child is likely to be sleepy, or the child may be sedated. - Lumbar puncture (for children in the autism). This test and the MRI may be done under sedation. Follow-Up Visits Follow-up visits are scheduled at different intervals, depending on study group, age and aspect of the study the child is enrolled in. The visits include a short interview session with the child's caregiver and assessment of the child's development and behavior. Some of the assessment measures used during the baseline examination are repeated, including symptoms ratings, behavioral tests and a blood test. For some children, the final visit will include repeats of the medical procedures.

NCT ID: NCT00280670 Completed - Anxiety Disorders Clinical Trials

CBT for Comorbid Anxiety Disorders in Children With Autism, Asperger Syndrome, or PDD-NOS

BIACA
Start date: January 2005
Phase: Phase 2
Study type: Interventional

This study is designed to examine the efficacy of a cognitive behavioral therapy (CBT) program for treating anxiety symptoms, social problems, and adaptive behavior deficits in children with autism spectrum disorders.

NCT ID: NCT00273650 Completed - Autistic Disorder Clinical Trials

Efficacy Study of Subcutaneous Methyl-B12 in Children With Autism

Start date: July 2005
Phase: Phase 2/Phase 3
Study type: Interventional

We will be testing a specific dietary supplement, methylcobalamin (vitamin B12). Follow-up assessments with our clinical team will take place over the 12-week study period so that we can record any changes in development. The main goal of this study is to determine if subcutaneous injections of vitamin B12 given every three days can positively affect behavior and development in children with autism. Hypothesis: Methylcobalamin injections will improve measures of executive function, speech, and socialization in children with autism, and will be associated with metabolic improvement.

NCT ID: NCT00263796 Completed - Autism Clinical Trials

An fMRI Study of the Effect of Intravenous Oxytocin vs. Placebo on Response Inhibition and Face Processing in Autism

Start date: March 2006
Phase: Phase 1
Study type: Interventional

To study the effect of oxytocin on face processing and response inhibition in autistic adults by fMRI.

NCT ID: NCT00263367 Completed - Autism Clinical Trials

Effect of Hyperbaric Therapy on Markers of Oxidative Stress in Children With Autism

Start date: October 2005
Phase: N/A
Study type: Interventional

This study will look at the changes taking place in the blood levels of key markers of oxidative stress. Oxidative stress is the biological equivalent of rust on a car. It changes vital cell chemistry. It is known to occur at high pressure oxygen, but little is known about changes at pressures slightly greater than normal atmospheric pressure. Hyperbaric therapy is used in a variety of medical conditions. It is being tested in this study only for safety. It is not being assessed for the ability of hyperbaric oxygen to improve the clinical condition of children with autism. This study was felt to be important since autism appears to be associated with oxidative stress and hyperbarics was being used "off-label" for this condition without safety studies.

NCT ID: NCT00261508 Completed - Autistic Disorder Clinical Trials

A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD)

Start date: August 1999
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the effectiveness of an oral solution of risperidone (an antipsychotic medication) versus placebo in the treatment of behavioral symptoms in children with Pervasive Developmental Disorders (PDD).

NCT ID: NCT00252603 Completed - Autism Clinical Trials

Galantamine Versus Placebo in Childhood Autism

Start date: April 2004
Phase: Phase 3
Study type: Interventional

Autism is a severe neurodevelopmental disorder that affects up to 16 in 10,000 individuals. It is a pervasive developmental disorder affecting social, communicative, and compulsive/repetitive behaviors characterized by stereotypic complex hand and body movements, craving for sameness, and narrow repetitive interests. Autism severely impacts both the affected individual and family members. The proposed study is designed to assess the efficacy of treatment with Galantamine vs. placebo in childhood/adolescent autism fulfilling DSM-IV and Autism Diagnostic Interview (ADI) criteria. We therefore hypothesize: 1. Galantamine will be superior to placebo in the acute treatment of global autism. 2. Galantamine will be superior to placebo in improving functional ability. 3. Galantamine will be superior to placebo in improving language function. 4. Galantamine will be superior to placebo improving irritable and hyperactive behavior. 5. Galantamine will be superior to placebo in improving social deficits.

NCT ID: NCT00251303 Completed - Clinical trials for Autism Spectrum Disorder

Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders

Start date: August 2005
Phase: Phase 2
Study type: Interventional

This study will examine the effectiveness of riluzole for treating Obsessive-Compulsive Disorder in Youth, Including those with Autism Spectrum Disorders.

NCT ID: NCT00247156 Completed - Autism Clinical Trials

An Autism Study Using Nambudripad's Food Allergy Elimination Treatments

Start date: November 2004
Phase: Phase 1/Phase 2
Study type: Interventional

1. We hypothesize that children in the experimental group will show a significant improvement over the control group as all food allergens groups and some other relevant allergenic substances are desensitized in a systematic way using the NAET® methodology within the specified period of study.

NCT ID: NCT00211796 Completed - Autism Clinical Trials

Divalproex Sodium ER in Adult Autism

Start date: April 2005
Phase: Phase 4
Study type: Interventional

12-week open label treatment trial of divalproex sodium extended release (Depakote ER) in 10 patients with a diagnosis of autism. Our objective is to determine how well these patients can tolerate the prescribed doses and what added benefits can be attributed to divalproex sodium ER.